Cargando…
Infarct quantification using 3D inversion recovery and 2D phase sensitive inversion recovery; validation in patients and ex vivo
BACKGROUND: Cardiovascular-MR (CMR) is the gold standard for quantifying myocardial infarction using late gadolinium enhancement (LGE) technique. Both 2D- and 3D-LGE-sequences are used in clinical practise and in clinical and experimental studies for infarct quantification. Therefore the aim of this...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029523/ https://www.ncbi.nlm.nih.gov/pubmed/24308673 http://dx.doi.org/10.1186/1471-2261-13-110 |
_version_ | 1782317222800130048 |
---|---|
author | Jablonowski, Robert Nordlund, David Kanski, Mikael Ubachs, Joey Koul, Sasha Heiberg, Einar Engblom, Henrik Erlinge, David Arheden, Håkan Carlsson, Marcus |
author_facet | Jablonowski, Robert Nordlund, David Kanski, Mikael Ubachs, Joey Koul, Sasha Heiberg, Einar Engblom, Henrik Erlinge, David Arheden, Håkan Carlsson, Marcus |
author_sort | Jablonowski, Robert |
collection | PubMed |
description | BACKGROUND: Cardiovascular-MR (CMR) is the gold standard for quantifying myocardial infarction using late gadolinium enhancement (LGE) technique. Both 2D- and 3D-LGE-sequences are used in clinical practise and in clinical and experimental studies for infarct quantification. Therefore the aim of this study was to investigate if image acquisitions with 2D- and 3D-LGE show the same infarct size in patients and ex vivo. METHODS: Twenty-six patients with previous myocardial infarction who underwent a CMR scan were included. Images were acquired 10-20 minutes after an injection of 0.2 mmol/kg gadolinium-based contrast agent. Two LGE-sequences, 3D-inversion recovery (IR) and 2D-phase-sensitive (PS) IR, were used in all patients to quantify infarction size. Furthermore, six pigs with reperfused infarction in the left anterior descending artery (40 minutes occlusion and 4 hours of reperfusion) were scanned with 2D- and 3D-LGE ex vivo. A high resolution T1-sequence was used as reference for the infarct quantification ex vivo. Spearman’s rank-order correlation, Wilcoxon matched pairs test and bias according to Bland-Altman was used for comparison of infarct size with different LGE-sequences. RESULTS: There was no significant difference between the 2D- and 3D-LGE sequence in left ventricular mass (LVM) (2D: 115 ± 25 g; 3D: 117 ± 24 g: p = 0.35). Infarct size in vivo using 2D- and 3D-LGE showed high correlation and low bias for both LGE-sequences both in absolute volume of infarct (r = 0.97, bias 0.47 ± 2.1 ml) and infarct size as part of LVM (r = 0.94, bias 0.16 ± 2.0%). The 2D- and 3D-LGE-sequences ex vivo correlated well (r = 0.93, bias 0.67 ± 2.4%) for infarct size as part of the LVM. The IR LGE-sequences overestimated infarct size as part of the LVM ex vivo compared to the high resolution T1-sequence (bias 6.7 ± 3.0%, 7.3 ± 2.7% for 2D-PSIR and 3D-IR respectively, p < 0.05 for both). CONCLUSIONS: Infarct quantification with 2D- and 3D-LGE gives similar results in vivo with a very low bias. IR LGE-sequences optimized for in vivo use yield an overestimation of infarct size when used ex vivo. |
format | Online Article Text |
id | pubmed-4029523 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-40295232014-05-22 Infarct quantification using 3D inversion recovery and 2D phase sensitive inversion recovery; validation in patients and ex vivo Jablonowski, Robert Nordlund, David Kanski, Mikael Ubachs, Joey Koul, Sasha Heiberg, Einar Engblom, Henrik Erlinge, David Arheden, Håkan Carlsson, Marcus BMC Cardiovasc Disord Research Article BACKGROUND: Cardiovascular-MR (CMR) is the gold standard for quantifying myocardial infarction using late gadolinium enhancement (LGE) technique. Both 2D- and 3D-LGE-sequences are used in clinical practise and in clinical and experimental studies for infarct quantification. Therefore the aim of this study was to investigate if image acquisitions with 2D- and 3D-LGE show the same infarct size in patients and ex vivo. METHODS: Twenty-six patients with previous myocardial infarction who underwent a CMR scan were included. Images were acquired 10-20 minutes after an injection of 0.2 mmol/kg gadolinium-based contrast agent. Two LGE-sequences, 3D-inversion recovery (IR) and 2D-phase-sensitive (PS) IR, were used in all patients to quantify infarction size. Furthermore, six pigs with reperfused infarction in the left anterior descending artery (40 minutes occlusion and 4 hours of reperfusion) were scanned with 2D- and 3D-LGE ex vivo. A high resolution T1-sequence was used as reference for the infarct quantification ex vivo. Spearman’s rank-order correlation, Wilcoxon matched pairs test and bias according to Bland-Altman was used for comparison of infarct size with different LGE-sequences. RESULTS: There was no significant difference between the 2D- and 3D-LGE sequence in left ventricular mass (LVM) (2D: 115 ± 25 g; 3D: 117 ± 24 g: p = 0.35). Infarct size in vivo using 2D- and 3D-LGE showed high correlation and low bias for both LGE-sequences both in absolute volume of infarct (r = 0.97, bias 0.47 ± 2.1 ml) and infarct size as part of LVM (r = 0.94, bias 0.16 ± 2.0%). The 2D- and 3D-LGE-sequences ex vivo correlated well (r = 0.93, bias 0.67 ± 2.4%) for infarct size as part of the LVM. The IR LGE-sequences overestimated infarct size as part of the LVM ex vivo compared to the high resolution T1-sequence (bias 6.7 ± 3.0%, 7.3 ± 2.7% for 2D-PSIR and 3D-IR respectively, p < 0.05 for both). CONCLUSIONS: Infarct quantification with 2D- and 3D-LGE gives similar results in vivo with a very low bias. IR LGE-sequences optimized for in vivo use yield an overestimation of infarct size when used ex vivo. BioMed Central 2013-12-05 /pmc/articles/PMC4029523/ /pubmed/24308673 http://dx.doi.org/10.1186/1471-2261-13-110 Text en Copyright © 2013 Jablonowski et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Jablonowski, Robert Nordlund, David Kanski, Mikael Ubachs, Joey Koul, Sasha Heiberg, Einar Engblom, Henrik Erlinge, David Arheden, Håkan Carlsson, Marcus Infarct quantification using 3D inversion recovery and 2D phase sensitive inversion recovery; validation in patients and ex vivo |
title | Infarct quantification using 3D inversion recovery and 2D phase sensitive inversion recovery; validation in patients and ex vivo |
title_full | Infarct quantification using 3D inversion recovery and 2D phase sensitive inversion recovery; validation in patients and ex vivo |
title_fullStr | Infarct quantification using 3D inversion recovery and 2D phase sensitive inversion recovery; validation in patients and ex vivo |
title_full_unstemmed | Infarct quantification using 3D inversion recovery and 2D phase sensitive inversion recovery; validation in patients and ex vivo |
title_short | Infarct quantification using 3D inversion recovery and 2D phase sensitive inversion recovery; validation in patients and ex vivo |
title_sort | infarct quantification using 3d inversion recovery and 2d phase sensitive inversion recovery; validation in patients and ex vivo |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029523/ https://www.ncbi.nlm.nih.gov/pubmed/24308673 http://dx.doi.org/10.1186/1471-2261-13-110 |
work_keys_str_mv | AT jablonowskirobert infarctquantificationusing3dinversionrecoveryand2dphasesensitiveinversionrecoveryvalidationinpatientsandexvivo AT nordlunddavid infarctquantificationusing3dinversionrecoveryand2dphasesensitiveinversionrecoveryvalidationinpatientsandexvivo AT kanskimikael infarctquantificationusing3dinversionrecoveryand2dphasesensitiveinversionrecoveryvalidationinpatientsandexvivo AT ubachsjoey infarctquantificationusing3dinversionrecoveryand2dphasesensitiveinversionrecoveryvalidationinpatientsandexvivo AT koulsasha infarctquantificationusing3dinversionrecoveryand2dphasesensitiveinversionrecoveryvalidationinpatientsandexvivo AT heibergeinar infarctquantificationusing3dinversionrecoveryand2dphasesensitiveinversionrecoveryvalidationinpatientsandexvivo AT engblomhenrik infarctquantificationusing3dinversionrecoveryand2dphasesensitiveinversionrecoveryvalidationinpatientsandexvivo AT erlingedavid infarctquantificationusing3dinversionrecoveryand2dphasesensitiveinversionrecoveryvalidationinpatientsandexvivo AT arhedenhakan infarctquantificationusing3dinversionrecoveryand2dphasesensitiveinversionrecoveryvalidationinpatientsandexvivo AT carlssonmarcus infarctquantificationusing3dinversionrecoveryand2dphasesensitiveinversionrecoveryvalidationinpatientsandexvivo |